PharmAbcine Raises $6 Million
PharmAbcine, a South Korea-based developer of monoclonal antibodies for the treatment of cancer and inflammatory diseases, has raised $6 million in Series A funding. OrbiMed's Caduceus Asia Partners and Novartis Korea Venture Fund co-led the round, and were joined by Green Cross, Tong Yang and Saehan Venture Fund.
17 September 2009•5 mins read
